Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 9, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Relapsed or Refractory Large B-cell Lymphoma
Interventions
BIOLOGICAL

Axicabtagene Ciloleucel

Administered intravenously

DRUG

Cyclophosphamide

Administered intravenously

DRUG

Fludarabine

Administered intravenously

DRUG

Dexamethasone

Administered orally or intravenously

Trial Locations (16)

21201

University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore

22908

University of Virginia Health System, Charlottesville

23219

Virginia Commonwealth University, Richmond

23502

Virginia Oncology Associates, Norfolk

29615

Prisma Health - Upstate, Greenville

37203

Tennessee Oncology, PLLC, Nashville

37232

Henry-Joyce Cancer Clinic, Nashville

45242

Oncology Hematology Care Clinical Trials, LLC, Cincinnati

48201

Barbara Ann Karmanos Cancer Institute, Detroit

78229

Methodist Healthcare System of San Antonio, San Antonio

80218

Colorado Blood Cancer Institute, Denver

84107

Intermountain Healthcare, Murray

84112

Huntsman Cancer Institute, University of Utah, Salt Lake City

90025

UCLA, Los Angeles

91010

City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte

07601

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack

All Listed Sponsors
lead

Kite, A Gilead Company

INDUSTRY